Interactions between methicillin and vancomycin in methicillin-resistant Staphylococcus aureus strains displaying different phenotypes of vancomycin susceptibility

Journal of Clinical Microbiology

Volumn 37, Issue 9, 1999, Pages 3068-3071

  Howe, Robin A ^a,c   Wootton, Mandy ^a,b   Bennett, Peter M ^b   MacGowan, Alasdair P ^a   Walsh, Timothy R ^b  

^a NORTH BRISTOL NHS TRUST   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c SOUTHMEAD HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

METICILLIN; VANCOMYCIN;

ARTICLE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG POTENTIATION; DRUG SENSITIVITY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL;

EID: 0032804789     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/jcm.37.9.3068-3071.1999     Document Type: Article

References (15)

1. Centers for Disease Control. 1997. Staphylococcus aureus with reduced susceptibility to vancomycin - United States, 1997. Morbid. Mortal. Weekly Rep. 46:765-756.
2. Chambers, H. F. 1997. Methicillin resistance in staphylococci: molecular and biochemical basis and clinical implications. Clin. Microbiol. Rev. 10:781-791.
3. de Lencastre, H., A. M. S. Figueiredo, And A. Tomasz. 1993. Genetic control of population structure in heterogeneous strains of methicillin resistant Staphylococcus aureus. Eur. J. Clin. Microbiol. Infect. Dis. 12(Suppl. 1):S13-S18.
4. Eliopoulos, E. M., and R. C. Moellering. 1996. Antimicrobial combinations, p. 330-396. In V. Lorian (ed.), Antibiotics in laboratory medicine, 4th ed. The Williams and Wilkins Co., Baltimore, Md.
5. Hiramatsu, K., N. Aritaka, H. Hanaki, S. Kawasaki, Y. Hosoda, and S. Hori. 1997. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 350:1670-1673.
6. Hiramatsu, K., H. Hanaki, T. Ino, K. Yabuta, T. Oguri, and F. C. Tenover. 1997. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J. Antimicrob. Chemother. 40:135-136.
7. Howe, R. A., K. B. Bowker, T. R. Walsh, T. G. Feest, and A. P. MacGowan. 1998. Vancomycin resistant Staphylococcus aureus. Lancet 351:602.
8. Jablonski, P. E., and M. Mychajlonka. 1988. Oxacillin-induced inhibition of protein and RNA synthesis in a tolerant Staphylococcus aureus isolate. J. Bacteriol. 170:1831-1836.
9. Matthews, P. R., and P. R. Stewart. 1984. Resistance heterogeneity in methicillin-resistant Staphylococcus aureus. FEMS Microbiol. Lett. 22:161-166.
10. National Committee for Clinical Laboratory Standards. 1997. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard. NCCLS publication M7-A4. National Committee for Clinical Laboratory Standards, Wayne, Pa.
11. Ploy, M. C., C. Grelaud, C. Martin, L. de Lumley, and F. Denis. 1998. First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital. Lancet 351:1212.
12. Sieradzki, K., and A. Tomasz. 1997. Inhibition of cell wall turnover and autolysis by vancomycin in a highly vancomycin-resistant mutant of Staphylococcus aureus. J. Bacteriol. 179:2557-2566.
13. Tenover, F. C., M. V. Lancaster, B. C. Hill, C. D. Steward, S. A. Stocker, G. A. Hancock, C. M. O'Hara, N. C. Clark, and K. Hiramatsu. 1998. Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides. J. Clin. Microbiol. 34:1020-1027.
14. Wootton, M., A. J. Hedges, K. E. Bowker, H. A. Holt, D. S. Reeves, and A. P. MacGowan. 1995. A critical assessment of the agar dilution chequerboard technique for studying in vitro antimicrobial interactions using a representative β-lactam, aminoglycoside, and fluoroquinolone. J. Antimicrob. Chemother. 35:569-576.
15. Wootton, M., R. A. Howe, T. R. Walsh, and A. P. MacGowan. 1998. Methodological factors in the detection of heterogeneously vancomycin-resistant Staphylococcus aureus (h-VRSA), abstr. C-139, p. 108. In Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.